The price of Elanco Animal Health Incorporated (NYSE:ELAN) shares last traded on Wall Street fell -4.04% to $8.54.
Based on available information, 11 analysts follow Elanco Animal Health Incorporated (NYSE:ELAN). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $19.00 and a low of $8.50, we find $13.00. Given the previous closing price of $8.90, this indicates a potential upside of 46.07 percent. ELAN stock price is now -8.81% away from the 50-day moving average and -32.40% away from the 200-day moving average. The market capitalization of the company currently stands at $4.31B.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
Among analysts, 6 rate the stock a hold while 3 rate it a buy. Brokers who have rated the stock have averaged $13.19 as their price target over the next twelve months.
With the price target maintained at $14, Barclays recently Upgraded its rating from Equal Weight to Overweight for Elanco Animal Health Incorporated (NYSE: ELAN). On August 18, 2022, Morgan Stanley Downgraded its previous ‘Overweight’ rating to ‘Equal-Weight’ on the stock reducing its target price from $37 to quote $22, while ‘JP Morgan’ rates the stock as ‘Neutral’.
In other news, HOOVER R DAVID, Director bought 5,000 shares of the company’s stock on Mar 14. The stock was bought for $47,750 at an average price of $9.55. Upon completion of the transaction, the Director now directly owns 165,000 shares in the company, valued at $1.41 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 13, Director HOOVER R DAVID bought 5,000 shares of the business’s stock. A total of $47,288 was incurred on buying the stock at an average price of $9.46. This leaves the insider owning 160,000 shares of the company worth $1.37 million. Insiders disposed of 424,309 shares of company stock worth roughly $3.62 million over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ELAN stock. A new stake in Elanco Animal Health Incorporated shares was purchased by BLACK CREEK INVESTMENT MANAGEMENT INC. during the first quarter worth $87,500,000. FRONTIER CAPITAL MANAGEMENT CO LLC invested $11,898,000 in shares of ELAN during the first quarter. In the first quarter, PROSHARE ADVISORS LLC acquired a new stake in Elanco Animal Health Incorporated valued at approximately $8,693,000. 1832 ASSET MANAGEMENT L.P. acquired a new stake in ELAN for approximately $8,626,000. LANDSCAPE CAPITAL MANAGEMENT, L.L.C. purchased a new stake in ELAN valued at around $8,226,000 in the second quarter. In total, there are 601 active investors with 99.10% ownership of the company’s stock.
A candlestick chart of Elanco Animal Health Incorporated (NYSE: ELAN) showed a price of $8.78 on Tuesday morning. During the past 12 months, Elanco Animal Health Incorporated has had a low of $8.50 and a high of $24.93. As of last week, the company has a debt-to-equity ratio of 0.80, a current ratio of 2.20, and a quick ratio of 1.20. The fifty day moving average price for ELAN is $9.32 and a two-hundred day moving average price translates $12.58 for the stock.
The latest earnings results from Elanco Animal Health Incorporated (NYSE: ELAN) was released for Mar, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.45, beating analysts’ expectations of $0.29 by 0.16. This compares to $0.10 EPS in the same period last year. The net profit margin was -0.50% and return on equity was -0.30% for ELAN. The company reported revenue of $1.26 billion for the quarter, compared to $1.23 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 2.53 percent. For the current quarter, analysts expect ELAN to generate $1.04B in revenue.
Elanco Animal Health Incorporated(ELAN) Company Profile
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. The company was founded in 1954 and is headquartered in Greenfield, Indiana.
